Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 2/20 | 0.46 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 3/20 | 0.43 |
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.39 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5776677 | 0.94 | FAAH (0.45) | PRMT5WDR77FAAHLTA4HROCK1 | |
| SCHEMBL5774446 | 0.93 | FAAH (0.46) | PRMT5WDR77FAAHLTA4HNPC1 | |
| SCHEMBL5777580 | 0.80 | FAAH (0.51) | FAAHKDM4ENPC1 | |
| SCHEMBL5775158 | 0.79 | FAAH (0.48) | FAAHKDM4ENPC1ACHE | |
| SCHEMBL5775017 | 0.79 | FAAH (0.50) | FAAHKDM4ENPC1 | |
| SCHEMBL4512639 | 0.78 | LTA4H (0.60) | LTA4HACHE | |
| SCHEMBL3271398 | 0.78 | LTA4H (0.60) | LTA4HACHE | |
| SCHEMBL5778653 | 0.77 | TMEM97 (0.50) | PRMT5WDR77FAAHKDM4ENPC1 | |
| SCHEMBL5778903 | 0.77 | C5AR1 (0.43) | PRMT5WDR77LTA4HROCK1ROCK2 | |
| Hydrochloric Acid SCHEMBL18038825 | 0.77 | LTA4H (0.58) | LTA4HACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936619-B2 | Cardiovascular disorders; antilipemic agents; sexual disorders | PFIZER, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| US-20040029859-A1 | Compounds useful in therapy | PFIZER INC. | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029859-A1 | Compounds useful in therapy | ADRA1D, HSD3B1, PTGER1 | PRMT5 2692/4885WDR77 2638/4885FAAH 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.